The US Food and Drug Administration (FDA) has approved Pacira Pharmaceuticals’ Exparel (bupivacaine liposome injectable suspension) 1.3% for post-surgical pain management.

Exparel is a multivesicular liposomal combined therapy product including bupivacaine, delivered using DepoFoam technology.

Exparel with DepoFoam delivers bupivacaine for an extended period of time, providing analgesia for up to 72 hours with reduced opioid consumption.

University of California surgery associate professor Sonia Ramamoorthy said that Exparel “has the potential to reduce or delay the use of opioids following inpatient and outpatient surgical procedures”.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now